Today: 30 June 2026
Browse Category

NASDAQ:TLX 11 December 2025 - 17 December 2025

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals Limited entered the spotlight again on December 17, 2025, as TLX stock extended its December sell-off amid a fast-moving mix of clinical-trial updates, regulatory overhang, and investor litigation headlines. Telix Pharmaceuticals+2Investing.com+2 On the ASX, Telix shares closed at A$11.73, down 6.61% on the session, with a wide intraday range from A$11.535 to A$12.730 and volume of roughly 6.36 million shares—a notably volatile day by recent standards. Investing.com+1
17 December 2025
···
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

December 11, 2025 Telix Pharmaceuticals Limited is ending 2025 in a paradoxical position: commercially successful, rich in late‑stage oncology assets, but trading near its 12‑month lows amid SEC scrutiny, an FDA setback and a growing stack of class‑action lawsuits. At the same time, new clinical milestones and a fresh collaboration with Varian are reinforcing the long‑term radiopharmaceutical growth story.
11 December 2025
···

Stock Market Today

  • SpaceX IPO: $5,000 In at the Open, Close, or High Shows Mixed Returns in Two Weeks
    June 30, 2026, 1:11 AM EDT. SpaceX shares started trading June 12 at $150 and ended the session near $161. A $5,000 buy at the open would get about 33 shares, worth $5,107 at the June 26 close of $153.23. Buyers at the close picked up 31 shares, now worth $4,750. Anyone paying the intraday high of $176 got 28 shares now valued at $4,351. Early numbers show SpaceX stock moved sharply in its first weeks as the company, which is unprofitable and building out its space-based AI platform, pushed for growth.
Go toTop